The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey

Future Medicine Ltd

Riham Abdel aziz , Simona Borilova , Hussein Khaled , Hoda Sayed Elkhodary , Joseph Gligorov , Mara Jidveian Popescu , Josiane Bassil , Erald Ruci , Ahmed Hadeya Osman Mousa , Fedro Peccatori , Hussam Zawam , Sabo Ademi , Maya Al Ghor , Ljiljana Vasic , Marina Iljovska , Miloš Krstić , Fadi Farhat , Amal El Mahfoudi , Jelena Dimitrijevic , Andra Mester , Bibiana Vertakova Krakovska , Mohamed Ait Erraisse , Erald Karaulli , Omar Awad , Vladimir Vidovic , Elona Tola , Nicholas Pavlidis , Mohamed Ezzeldin , Jelena Popovic , Hanady Mahmoud Hegazy , Haifaa Dbouk , Valentina Bojovska Trajanovska , Miljana Dzunic , Erns Sehic-Kozica , Arda Isik , Elsa Rawadi , Gordana Berić Jozić , Ramona Matei , Afif Mohammed , Vladimir Todorović , Manjola Qordja , Cristiana Bianca Omut , Fedja Djordjevic , Haitham Shaheen , Caroline Fikry , Fatima Zahra Hijri , Ebtehal Salah , Matti Aapro , Khaled Khalil , Fadi Haddad , Soufiane Khelifi Touhami , Jalal Qawasmeh , Pantelimon Iuliana , Damir Vrbanec , Alex Eniu , Mohyeldin Saber Abdelhalim , Jonida Tula , Mohammed Ezzi , Fatma Abdelbakey , Mohamed Shouman , Abraham Kuten , Elie Rassy , Kleva Qeraj , Youstina Youstina , Manjola Luzi , Selma Subasic-Tankovic , Marija Simonovska , Mariam Mohsen Khalil , Mohamed Ismail , Popescu Andrei , Mariam Mohsen Khalil , Andrje Zist , Joseph Kattan , Moldoveanu Vanessa , Barbara Ziolkowska , Assia Konsoulova , Jasmina Djundeva , Vještica Milka , Anastela Mano , Eleni Xenophontos , Elma Kapisazovic , Nikola Milasevic , Samra Sulejmanovic , Hanan Atef Elnemr , Pamela Abdayem , Silvia Mosoiu , Hamid Elia Daaboul , Vesna Ceriman Krstic

Preuzmite dokument

2021

Aim: To report on the management strategies in patients with cancer of unknown primary (CUP) in middle-income countries. Methods: We conceived a survey of 20 items concerning the management of patients with CUP in daily clinical practice. Only participants from lower- and higher-middle-income countries, as per the World Bank Classification, were eligible for this study. Results: The indications for the first-line treatment did not differ between the two economic regions, whereas those for second-line treatment were more prevalent in higher-middle-income countries. The use of targeted therapy based on immunohistochemistry alone was higher in lower-middle-income countries, although the access to CUP classifiers was similar between the two regions. Conclusions: Proper recommendations must ensure that the economic burden is minimized and that other benefits outweigh the limited survival benefit achieved in patients with CUP.